ABstRACt. Ginkgo biloba (Egb 761) extract, the most prescribed phytomedicine in Europe for the treatment of cerebral insufficiency and vascular diseases, was tested for its possible protective effects against mitomycin C (MMC)-and cyclophosphamide (CP)-induced mutagenicity using the micronucleus test in mouse bone marrow. The extract was co-administered to mice at doses of 50, 100 and 200 mg/kg (po) with 4 mg/kg (ip) MMC or 24 mg/kg (ip) CP. All doses of Egb 761 were significantly (P < 0.05) effective in reducing the frequency of micronucleated polychromatic erythrocytes, when compared with MMC or CP alone. Based on these results, we suggest that Egb 761 possesses both direct and indirect antimutagenic potential.
Animals
Healthy young adult (8-12 weeks) males of Mus musculus (Swiss Webster out bred mice), weighing 25-30 g, obtained from the Central Animal House of Universidade Federal de Goiás, were used in the studies. All animals were brought to the laboratory 5 days before the experiments. They were housed in plastic cages (40 x 30 x 16 cm) at 24 ± 2°C and 55 ± 10% humidity, with a natural light-dark cycle of 12 h. Food (appropriate commercial ration; Labina, Ecibra Ltda.) and water were provided ad libitum.
Experimental procedure (micronucleus test)
Five animal groups were co-treated by gavage with 50, 100, and 200 mg/kg Egb 761 and 4 mg/kg MMC (ip) or 24 mg/kg CP (ip) (Salamone et al., 1980) . The positive (MMC = 4 mg/kg and CP = 24 mg/kg) and negative control groups (0.1 mL/10 g body weight sterilized distilled H 2 O) were also included. After the periods of treatments (36 h for MMC and 48 h for CP), the animals were sacrificed. The femurs were exposed and cleaned, and the epiphysis sectioned. The bone marrow was gently flushed out using fetal bovine serum. After centrifugation (1500 rpm, 5 min), bone marrow cells were smeared on glass slides, coded for blind analysis, air-dried and placed in absolute methanol for 5 min. The smears were stained with Giemsa for detecting micronucleated polychromatic erythrocytes (MNPCE) (Schmid, 1975) . For each animal, three slides were prepared and 1000 polychromatic erythrocytes (PCE) were counted to determine the frequency of MNPCE. To determine the cytotoxicity of the plant extract, 1000 normochromatic erythrocytes (NCE) were counted, as well as the frequency of PCE within the same microscope fields. The PCE/NCE ratio was then calculated. The slides were analyzed using an Olympus BH-2 microscope (1000x).
statistical analysis
The results of the antimutagenicity tests were tabulated and experimental values are reported as means ± standard deviation. One-way independent sample ANOVA was used to detect differences between the doses of Egb 761 in the same co-treatment (MMC or CP). The Tukey post hoc test was then used when necessary. Pearson correlation was used to verify the association between the results obtained with both co-administrations. The percentage of inhibition (%I) was measured by the complement of the rate between the average frequency of MNPCE of the test treatment and the average frequency of MNPCE of the positive control times 100 (%I = 1-(MNPCE (Egb 761 and MMC or CP) / MNPCE (MMC or CP)) x 100). The cytotoxicity data were expressed as the PCE/NCE ratio, and the analyses were performed using the non-parametric Kruskal-Wallis test followed by the Mann-Whitney test, for the difference against positive controls.
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REsuLts And dIsCussIon
The antimutagenic analyses are shown in Table 1 . Our results demonstrate that Egb 761 was able to significantly protect (P < 0.05) DNA from the mutagens studied when compared with each positive control (MMC or CP), at all doses tested. The determination coefficient (R 2 ) between the two antimutagenic profiles was 53.29% (P < 0.0003). In the light of these results, it is possible that common mechanisms of action of the extract, such as antioxidant activity, free radical scavenging and even gene regulation, could contribute to its direct and indirect antimutagenic profile. The use of MMC as an antitumor drug is due to its direct action on DNA. At least two different processes are responsible for its biological effects: DNA alkylation (which can lead to cross links) and the generation of free radicals, such as superoxide and hydroxy radicals (which can lead to DNA strand breaks) (Kang et al., 2006) . On the other hand, the alkylating agent CP is one of a group of anticancer drugs that are administered as inactive prodrugs and that are activated in vivo via one or more metabolic steps. It is known that the initial step in the bioactivation of cyclophosphamide involves cytochrome P-450-mediated hydroxylation at C-4 ( LeBlanc and Waxman, 1990) .
Until now, the literature has demonstrated that Egb 761 has antioxidant properties, can act as a free radical scavenger and anti-inflammatory agent, can improve cognition, memory and anxiety, and can affect gene regulation (Gaudineau et al., 2004; Chen et al., 2005; Ergun et al., 2005; Krizková et al., 2008) . It is also possible that direct interactions between the Egb 761 extract and these mutagens occur, since it has been pointed out that commonly used herbal medicines cause some herb-drug interactions (Izzo and Ernst, 2001; Williamson, 2001) . Egb 761 itself has been reported to interact with some drugs, such as aspirin, acetaminophen or warfarin, provoking occurrences of cerebral and subarachnoid hemorrhage (Vaes and Chyka, 2000) .
No significant difference (P > 0.05) in the frequency of MNPCE was observed among the Egb 761 doses co-administrated with MMC and no significant difference (P > 0.05) was observed among the treatments and positive control PCE/NCE ratio ( Table 1) . The co-administration of Egb 761 and CP, on the other hand, revealed a significant increase in the PCE/NCE ratio and a significant difference (P < 0.05) among the MNPCE frequen-cies (Table 1) . The higher dose, 200 mg/kg Egb 761 and CP, caused a substantial augmentation of the %I, compared with the doses of 50 and 100 mg/kg. The %I of the treatment with 200 mg/kg Egb 761 and MMC was 51.16% and %I of the treatment with 200 mg/kg Egb 761 and CP was 71.54%, which suggests that the standardized Ginkgo extract was more effective in the modulation of the mutagenic potential and cytotoxicity of the indirectacting drug CP. Despite the conflicting results obtained when the ability of the standardized Ginkgo extract or its constituents to modulate the cytochrome P-450 (CYP) was evaluated (Kuilman et al., 2000; Budzinski et al., 2000; Lautraite et al., 2002; Huynh and Teel, 2002) , the effectiveness of the Egb 761 extract in the modulation of CP mutagenicity and cytotoxicity could be related to the inhibition of some CYP enzymes, which was demonstrated by Qualls et al. (1998) . In this manner, changes in the level of expression of hepatic P-450s could affect the level of cyclophosphamide metabolism and, accordingly, its efficacy.
Other studies also support the antigenotoxic potential of Ginkgo biloba. Nunes (2004) observed its protective effect against doxorubicin (which can act as an intercalating antitumor drug or by the generation of reactive oxygen species) (Tewey et al., 1984) in D. melanogaster, and Krizková et al. (2008) related its antimutagenic action against ofloxacin and acridine orange in the flagellate E. gracilis. In conclusion, our results suggest for the first time that the standardized extract of this plant shows medicinal potential as an antimutagenic agent, modulating the mutagenicity caused by both direct-and indirect-acting chemical mutagens, in a mammalian model.
